Zoetis Inc. (NYSE:ZTS) Stock Holdings Trimmed by Kathmere Capital Management LLC

Kathmere Capital Management LLC reduced its position in Zoetis Inc. (NYSE:ZTS) by 2.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,155 shares of the company’s stock after selling 110 shares during the quarter. Kathmere Capital Management LLC’s holdings in Zoetis were worth $703,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mutual Advisors LLC grew its holdings in shares of Zoetis by 4.0% during the third quarter. Mutual Advisors LLC now owns 3,195 shares of the company’s stock valued at $556,000 after purchasing an additional 122 shares during the last quarter. Mather Group LLC. grew its holdings in shares of Zoetis by 2.0% during the third quarter. Mather Group LLC. now owns 3,638 shares of the company’s stock valued at $633,000 after purchasing an additional 73 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in shares of Zoetis by 25.5% during the third quarter. Tower Research Capital LLC TRC now owns 19,388 shares of the company’s stock valued at $3,373,000 after purchasing an additional 3,938 shares during the last quarter. Bank of Nova Scotia grew its holdings in shares of Zoetis by 1.2% during the third quarter. Bank of Nova Scotia now owns 135,266 shares of the company’s stock valued at $23,532,000 after purchasing an additional 1,643 shares during the last quarter. Finally, Ironwood Investment Counsel LLC bought a new position in shares of Zoetis during the third quarter valued at approximately $1,049,000. 92.80% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on ZTS shares. Piper Sandler reaffirmed an “overweight” rating and set a $195.00 target price (down from $220.00) on shares of Zoetis in a report on Tuesday, April 16th. Barclays reduced their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating for the company in a research report on Tuesday, April 23rd. HSBC reduced their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. The Goldman Sachs Group reduced their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating for the company in a research report on Monday, May 6th. Finally, Stifel Nicolaus reduced their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a research report on Tuesday, April 30th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Zoetis has a consensus rating of “Buy” and an average target price of $211.75.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the company’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares of the company’s stock, valued at $2,237,316. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is currently owned by insiders.

Zoetis Stock Performance

ZTS opened at $173.36 on Friday. The company has a market capitalization of $79.10 billion, a price-to-earnings ratio of 33.40, a price-to-earnings-growth ratio of 2.69 and a beta of 0.88. The company has a debt-to-equity ratio of 1.30, a current ratio of 3.33 and a quick ratio of 1.94. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $201.92. The business has a 50 day moving average price of $168.69 and a two-hundred day moving average price of $178.72.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to the consensus estimate of $2.14 billion. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.31 earnings per share. Research analysts predict that Zoetis Inc. will post 5.76 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 4th. Shareholders of record on Thursday, July 18th will be given a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a yield of 1.00%. Zoetis’s dividend payout ratio (DPR) is 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.